The Marqués de Valdecilla University Hospital, mainly known as Valdecilla, is a general hospital located in the city of Santander, Cantabria, in Spain.

There are 907 beds in Hospital Universitario Marques de Valdecilla.

During the past decade, Hospital Universitario Marques de Valdecilla conducted 440 clinical trials. In the 10-year time frame, 440 clinical trials started and 132 clinical trials were completed, i.e. on average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 231 clinical trials started and 89 clinical trials were completed. i.e. 38.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Marques de Valdecilla" #1 sponsor was "Hoffmann-La Roche" with 40 trials, followed by "PETHEMA Foundation" with 31 trials sponsored, "Janssen Research & Development, LLC" with 30 trials sponsored, "Pfizer" with 23 trials sponsored and "Celgene" with 23 trials sponsored. Other sponsors include 469 different institutions and companies that sponsored additional 252 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Marques de Valdecilla" #1 collaborator was "Instituto de Investigación Marqués de Valdecilla" with 15 trials as a collaborator, "Centro de Investigación Biomédica en Red de Salud Mental" with 13 trials as a collaborator, "AstraZeneca" with 7 trials as a collaborator, "Bristol-Myers Squibb" with 7 trials as a collaborator and "Eli Lilly and Company" with 6 trials as a collaborator. Other collaborators include 282 different institutions and companies that were collaborators in the rest 221 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Marques de Valdecilla" are "Multiple Myeloma" (27 trials), "Coronary Artery Disease" (17 trials), "Schizophrenia" (17 trials), "Breast Cancer" (10 trials) and "Nonalcoholic Steatohepatitis" (8 trials). Many other conditions were trialed in "Hospital Universitario Marques de Valdecilla" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Marques de Valdecilla" are "Drug" (444 trials), "Other" (62 trials), "Device" (50 trials), "Biological" (45 trials) and "Procedure" (25 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (115 trials), "Dexamethasone" (17 trials), "Gemcitabine" (13 trials), "Paclitaxel" (12 trials) and "Prednisone" (12 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Marques de Valdecilla" are 586 trials for "All" genders, 17 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are 229 active trials in "Hospital Universitario Marques de Valdecilla". 3 are not yet recruiting, 148 are recruiting, 77 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 271 completed trials in Hospital Universitario Marques de Valdecilla, 3 suspended trials, and 62 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Marques de Valdecilla, 46 "Phase 1" clinical trials were conducted, 171 "Phase 2" clinical trials and 213 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 59 trials, and there were also 29 trials that are defined as “Not Applicable".